CCCC – c4 therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology [Yahoo! Finance]
C4 Therapeutics, Inc. (NASDAQ: CCCC) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $8.00.
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
Form 8-K C4 Therapeutics, Inc. For: Dec 09
Form 4 C4 Therapeutics, Inc. For: Nov 19 Filed by: Hoerter Steven L.
Form 3 C4 Therapeutics, Inc. For: Nov 19 Filed by: Hoerter Steven L.
Form 8-K C4 Therapeutics, Inc. For: Nov 20
Form 144 C4 Therapeutics, Inc. Filed by: Salter Malcolm
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.